Beyond Weight Loss
When the SELECT trial published its results in 2023, it changed the conversation about GLP-1 medications permanently. The trial enrolled over 17,500 adults with obesity and established cardiovascular disease — but without diabetes — and found that semaglutide reduced the risk of major adverse cardiovascular events including heart attack, stroke, and cardiovascular death by 20% compared to placebo.
The significance of this finding extended in two important directions. First, the benefit was seen in people without diabetes. Second, the cardiovascular protection appeared to go beyond what weight loss alone would predict — suggesting GLP-1 has direct effects on the heart and blood vessels independent of how much weight a person loses.
How GLP-1 Protects the Heart
Direct Receptor Effects
GLP-1 receptors are present in the heart muscle and coronary blood vessels. Activation of these receptors has been shown in laboratory studies to reduce inflammation in arterial walls, improve heart muscle function after injury, and reduce the extent of damage caused by reduced blood flow. These direct effects are believed to contribute meaningfully to the cardiovascular benefits observed in humans.
Metabolic Improvements
GLP-1 medications improve multiple metabolic cardiovascular risk factors simultaneously — blood pressure, blood sugar, triglycerides, and body weight. Each improvement independently reduces cardiovascular risk, and their combined effect is greater than any single change alone.
Inflammation Reduction
Chronic low-grade inflammation is a major driver of atherosclerosis and cardiovascular disease. GLP-1 medications have demonstrated measurable anti-inflammatory effects in multiple studies, which may partly explain why their heart benefits exceed what weight loss alone would predict.
What This Means for GLP-1 Users
If you are on a GLP-1 medication primarily for weight loss, you are likely also receiving meaningful cardiovascular protection — particularly if you have existing risk factors like high blood pressure, elevated cholesterol, or a family history of heart disease.
In March 2024, the FDA approved semaglutide (Wegovy) specifically for reducing cardiovascular risk in adults with obesity — making it the first obesity medication ever approved for a cardiovascular indication.